AbbVie submits NDA to Japanese regulators for ombitasvir/ paritaprevir/ ritonavir combination in hepatitis C
US drugmaker AbbVie (NYSE: ABBV) has submitted a New Drug Application to the Japanese Ministry of Health, Labor and Welfare for its ombitasvir/paritaprevir/ritonavir combination for genotype 1 chronic hepatitis C infection.
The combination is an investigational, all-oral, ribavirin- and interferon-free, 12-week, direct-acting antiviral treatment dosed once-daily. The NDA is supported by the Phase III GIFT-I study, which met its primary endpoint. It achieved a 95% sustained virologic response rate at 12 weeks post-treatment in the subgroup of previously untreated, non-cirrhotic, adult genotype 1b-infected Japanese patients who were eligible for therapy with IFN and had a high viral load. Two patients without cirrhosis discontinued treatment due to adverse events.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze